CRISPR–Cas13: Pioneering RNA Editing for Nucleic Acid Therapeutics

TL;DR

CRISPR–Cas13 is a new tool for editing RNA, which can help treat diseases by targeting RNA without changing DNA.

Contribution

This review highlights the novel use of CRISPR–Cas13 for RNA editing and its potential in developing nucleic acid therapeutics.

Findings

CRISPR–Cas13 targets RNA, avoiding genomic instability seen with DNA-targeting CRISPR.

It can suppress disease-causing genes and correct splicing errors.

Challenges include improving specificity and delivery methods for clinical use.

Abstract

The CRISPR–Cas13 system has emerged as a revolutionary tool for RNA editing, offering new opportunities for the development of nucleic acid therapeutics. Unlike DNA-targeting CRISPR–Cas9, Cas13 targets and cleaves RNA, enabling gene silencing and preventing genomic instability. Its applications include suppressing disease-causing genes, correcting splicing errors, and modulating immune responses. Despite these advances, challenges persist, such as the need to refine specificity, mitigate off-target impacts, and ensure effective delivery. This review provides an overview of the CRISPR–Cas13 mechanism, elucidating its role in RNA-targeted therapies and its transformative potential for disease treatment. Furthermore, it addresses the ongoing challenges that the scientific community is striving to overcome.

Figures